Reading ANRO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANRO free→Reading ANRO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANRO free→QuarterlyIQ Insights · ANRO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Andrew Miller, Ph.D. to the Board On May 27 , 2026, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board. Effective March 16,…
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Equity Plan Amendments As noted in
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Entry Into A Material Definitive Agreement. Private Placement of Common Stock and Warrants On March 16, 2026, Alto Neuroscience, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 2,900,000 shares (the “ Shares ”) of the Company’s common stock, par val…
Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreement as set forth under
Other Events. On March 16, 2026, the Company issued a press release entitled “Alto Neuroscience Announces $120 Million Private Placement Financing.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
of this Current Report (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreement as set forth under
Entry Into A Material Definitive Agreement. Private Placement of Common Stock and Warrants On October 19, 2025, Alto Neuroscience, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional and other accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 3,832,263 shares (the “ Shares ”) of the Company’…
Other Events. On October 20, 2025, the Company issued a press release entitled “Alto Neuroscience Announces $50 Million Private Placement Financing.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company concurrently issued a press release entitled “Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA…
Termination of a Material Definitive Agreement. As previously disclosed, on February 3, 2025, the Company entered into a Sales Agreement (the “ Sales Agreement ”) with Leerink Partners LLC (the “ Agent ”), pursuant to which the Company from time to time may offer and sell shares of its common stock through or to the Agent having an aggregate offering price of up to $75 million. On October 20, 2025, the Company delivered written notice to the Agent to terminate the Sales Agreement, effective O…
of this Current Report (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Raymond Sanchez, M.D. to the Board On August 12, 2025, the Board of Directors (the “Board”) of the Company, following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), increased the size of the Board from five to six members and unanimously appointed Ramiro (Raymond) Sanchez, M.D. to serve…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Repricing of Designated Underwater Options On July 3, 2025, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”) approved an option repricing, which was effective at the close of market on July 3, 2025 (the “Effective Date”). The repricing generally applies to options to purchase shares of the Company’s common stock t…
Other Events. On June 3, 2025, Alto Neuroscience, Inc. issued a press release entitled “Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Pivotal Trial Readout in Treatment Resistant Depression Within Current Cash Runway.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Entry Into A Material Definitive Agreement. On May 31, 2025 (the “Closing Date”), Alto Neuroscience, Inc. (the “Company”), and Chase Therapeutics Corporation (the “Seller”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) pursuant to which the Seller sold its rights, title, and interest in and to certain assets related to a novel combination of pramipexole and ondansetron, known as CTC-501, and a novel combination of pramipexole and aprepitant, known as CTC-413 (the…
The issuance of shares of the CTC Shares will be made in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D thereunder.
of this Current Report (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 17, 2025, Jeff (Po Yu) Chen, Ph.D. informed the Company's board of directors (the "Board") that he will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders. Dr. Chen's decision was not the result of any disagreement with the Company or any matter relating to the Company’s operations, policie…
Entry into a Material Definitive Agreement. On January 13, 2025 (the “Effective Date”), Alto Neuroscience, Inc. (the “Company”) entered into that certain First Amendment to Loan and Security Agreement (the “Amendment”) with K2 HealthVentures LLC as lender (the “Lender”) and administrative agent (in such capacity, the “Administrative Agent”) and Ankura Trust Company, LLC, as collateral agent (in such capacity, the “Collateral Trustee”). The Amendment amended the terms of that certain Loan and…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
The issuance of shares of the Company’s common stock underlying the Warrants and the Conversion Shares will be made in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D thereunder.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.